Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06960083

Transcranial Magnetic Stimulation in Misophonia

The purpose of the project is to assess the efficacy of parietal transcranial magnetic stimulation in misophonia. N=60 participants will undergo two transcranial magnetic stimulation sessions: one inhibitory and another excitatory. During both sessions, the parietal region will be stimulated. Participants will perform computerized tasks immediately before and after the stimulation, while EEG, heart rate, and skin temperature will be recorded. These recordings will be used to assess if TMS can be used to improve tolerance to misophonia triggers.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Misophonia

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mount Sinai West

New York, 10022, United States

Location status: Recruiting

Location contact

Daniela Schiller, PhD

CONTACT

[email protected]

Martijn Figee, MD, PhD

CONTACT

[email protected]

Parul Jain

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear.
  • Must be between the ages of 18 - 55.
  • Must be fluent in English since the study's instructions, surveys, and tasks will be in English.

Exclusion criteria

  • Epilepsy or previous episode of convulsion or seizure.
  • Previous episode of fainting spell or syncope.
  • Head trauma.
  • Hearing problems.
  • Cochlear implant.
  • Metal in the brain, skull, or anywhere else in the body (e.g., splinters, fragments, clips, etc.).
  • Implanted neurostimulator (e.g., DBS, epidural/subdural, VNS).
  • Presence of cardiac pacemaker or intracardiac lines.
  • Presence of medication infusion device.
  • Use of pro-convulsant or epileptogenic medications.
  • Pregnancy. The risks associated with TMS exposure during gestation have not been studied extensively. We wish to safeguard the health of potential participants and their children.
  • Lactation. The risks associated with TMS during lactation and its effects on infant development have not been studied. We wish to safeguard the health of potential participants and their children.
  • Presence of Mania, Psychosis, Antisocial Personality Disorder, Borderline Personality Disorder, and Suicidal Ideation.

Treatment and study plan

Transcranial magnetic stimulation (TMS)

Other

Transcranial Magnetic Stimulation (TMS) is an FDA-approved non-invasive brain stimulation technology. It is currently used for treating depression. Applications to other disorders such as OCD and anxiety using TMS are currently under investigation. TMS will be administered for 25 minutes.

Primary outcomes

  1. Unpleasantness Rating Scale

    Time frame: after each session, 72 hours apart (each session is 2 hours)

    Participants will be presented with a slider with extremes labelled as extremely unpleasant and extremely pleasant. Ratings will be provided for audio clips and visual cues. Full scale from 0-100, higher score indicates more unpleasantness

Secondary outcomes

  1. Heart Rate

    Time frame: after each session, 72 hours apart (each session is 2 hours)

    The heart rate (number of beats per minute) will be measured using a wristwatch worn by the participant.

  2. Skin Conductance Response

    Time frame: after each session, 72 hours apart (each session is 2 hours)

    Skin conductance, a measure capturing the amount of sweat, will be measured using a wristwatch worn by the participant.

  3. EEG P1-N1-P2 Complex Peak Amplitude

    Time frame: after each session, 72 hours apart (each session is 2 hours)

    Amplitude (microvolts) of P1, N1, and P2 peaks measured in the parietal region

  4. EEG P1-N1-P2 Complex Peak Latency

    Time frame: after each session, 72 hours apart (each session is 2 hours)

    Latency (milliseconds) of P1, N1, and P2 peaks measured in the parietal region

  5. EEG Frequency Band Amplitude

    Time frame: after each session, 72 hours apart (each session is 2 hours)

    Amplitude (decibel) in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region

  6. EEG Frequency Band Inter-Trial Coherence

    Time frame: after each session, 72 hours apart (each session is 2 hours)

    Coherence (unitless) across trials in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region

Study contacts

Contact information is provided by the study sponsor or research team.

Parul Jain, PhD

CONTACT

[email protected]

212-824-8992

Shama Patel

CONTACT

[email protected]

347-670-4878

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Registry information

Official study title

A Transcranial Magnetic Stimulation Approach to Treat Misophonia

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 7, 2025
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.